Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. Stone GW, et al. Among authors: hagiwara n. J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4. J Am Coll Cardiol. 2011. PMID: 21470815 Free article. Clinical Trial.
Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
Sugiura R, Ogawa H, Oka T, Koyanagi R, Hagiwara N; HIJ-CREATE Investigators. Sugiura R, et al. Among authors: hagiwara n. Am J Cardiol. 2012 Feb 15;109(4):576-80. doi: 10.1016/j.amjcard.2011.09.050. Epub 2011 Nov 16. Am J Cardiol. 2012. PMID: 22100194 Clinical Trial.
Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents.
Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, Stone GW, Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD. Saito S, et al. Among authors: hagiwara n. J Cardiol. 2014 Aug;64(2):105-12. doi: 10.1016/j.jjcc.2013.12.003. Epub 2014 Jan 23. J Cardiol. 2014. PMID: 24462183 Free article. Clinical Trial.
A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, Saito S, Yajima J, Hagiwara N, Mitsudo K, Popma JJ, Serruys PW, Onuma Y, Ying S, Cao S, Staehr P, Cheong WF, Kusano H, Stone GW; ABSORB Japan Investigators. Kimura T, et al. Among authors: hagiwara n. Eur Heart J. 2015 Dec 14;36(47):3332-42. doi: 10.1093/eurheartj/ehv435. Epub 2015 Sep 1. Eur Heart J. 2015. PMID: 26330419 Clinical Trial.
Multislice computed tomography assessment of everolimus-eluting Absorb bioresorbable scaffolds in comparison with metallic drug-eluting stents from the ABSORB Japan randomised trial.
Tanabe K, Popma JJ, Kozuma K, Saito S, Muramatsu T, Nakamura S, Namiki A, Morino Y, Hagiwara N, Uematsu M, Kawasaki T, Fujii K, Serruys PW, Onuma Y, Ying S, Kusano H, Stone GW, Kimura T. Tanabe K, et al. Among authors: hagiwara n. EuroIntervention. 2018 Oct 12;14(9):e1020-e1028. doi: 10.4244/EIJ-D-17-00716. EuroIntervention. 2018. PMID: 29131799 Free article. Clinical Trial.
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.
Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Rabinowitz A, Carrié D, Pompili V, Bouchard A, Saito S, Allocco DJ, Dawkins KD, Stone GW. Kelly CR, et al. Among authors: hagiwara n. JACC Cardiovasc Interv. 2017 Dec 11;10(23):2392-2400. doi: 10.1016/j.jcin.2017.06.070. JACC Cardiovasc Interv. 2017. PMID: 29217001 Free PMC article. Clinical Trial.
Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER.
Kawada-Watanabe E, Yamaguchi J, Kanbayashi K, Sekiguchi H, Arashi H, Ogawa H, Hagiwara N. Kawada-Watanabe E, et al. Among authors: hagiwara n. Am J Cardiol. 2018 Dec 1;122(11):1817-1823. doi: 10.1016/j.amjcard.2018.08.028. Epub 2018 Sep 8. Am J Cardiol. 2018. PMID: 30270178 Clinical Trial.
804 results